

Table of Contents

TABLE OF CONTENTS.....	1
1 INTRODUCTION.....	4
1.1 VENTRAL MIDLINE DEVELOPMENT	4
1.1.1 <i>Craniofacial development</i>	7
1.1.2 <i>Heart development</i>	8
1.1.3 <i>Ephrins as NCC pathfinders</i>	9
1.1.4 <i>Midline development and disease</i>	10
1.2 X-LINKED OPITZ BBB/G SYNDROME (OS) AND MID1	11
1.2.1 <i>The RBCC protein MID1</i>	12
1.2.2 <i>The MID1 function</i>	15
1.2.3 <i>Regulation of MID1 function.</i>	16
1.3 MTOR PATHWAY	17
1.4 AIM OF THE STUDY	19
2 MATERIALS AND METHODS.....	20
2.1 MATERIALS	20
2.1.1 <i>General reagents</i>	20
2.1.2 <i>Enzymes</i>	22
2.1.3 <i>Kits</i>	22
2.1.4 <i>Instruments and Disposables</i>	22
2.1.5 <i>Antibodies</i>	23
2.1.6 <i>Vectors</i>	24
2.1.7 <i>Buffers and Media</i>	24
2.1.8 <i>Cell lines</i>	26
2.1.9 <i>Bioinformatic tools and Databases</i>	26
2.1.10 <i>Patients</i>	27
2.2 NUCLEIC ACID METHODS	27
2.2.1 <i>Polymerase chain reaction (PCR)</i>	27
2.2.2 <i>Agarose gel electrophoresis</i>	28
2.2.3 <i>RNA preparation and cDNA synthesis</i>	28
2.2.4 <i>Phenol:Chloroform extraction</i>	29
2.2.5 <i>EtOH precipitation of nucleic acids</i>	29
2.2.6 <i>Cloning</i>	29
2.2.6.1 Cloning of pEGFP constructs and mutagenesis	29
2.2.6.2 Preparation of the pCMVTag2C and pBMT116 constructs.....	31
2.2.6.3 α 4/44aa peptide clones.....	31
2.2.7 <i>Plasmid DNA isolation and transformation</i>	32
2.2.7.1 Plasmid DNA isolation.....	32
2.2.7.2 Chemical transformation	33
2.2.7.3 Electroporation	33
2.2.8 <i>Transfection</i>	33
2.2.8.1 siRNA transfection	33
2.2.8.2 Polyfect transfection of plasmid DNA	33
2.2.8.3 Lipofectamine transfection of plasmid DNA	34
2.2.9 <i>Sequencing</i>	34
2.3 PROTEIN METHODS	35

2.3.1	<i>Bradford assay</i>	35
2.3.2	<i>SDS-PAGE Gel</i>	35
2.3.3	<i>Western blot</i>	36
2.3.4	<i>Silver staining</i>	37
2.3.5	<i>Coomassie/Colloidal coomassie staining</i>	37
2.3.6	<i>Immunofluorescence</i>	37
2.3.7	<i>Microtubule assembly experiment</i>	38
2.3.8	<i>Immunoprecipitation</i>	38
2.3.9	<i>Yeast two-hybrid experiments</i>	39
2.3.9.1	<i>Yeast-transformation</i>	39
2.3.9.2	β - <i>Galactosidase activity</i>	40
2.3.10	<i>Cell culturing and trypsinisation</i>	41
2.4	PREPARATION OF THE 44AA PEPTIDES	41
2.4.1	<i>Growth of E.Coli cultures</i>	41
2.4.2	<i>Preparation of cleared E.Coli lysates</i>	42
2.4.3	<i>Purification of 6xHis tagged proteins from E.Coli</i>	42
2.4.4	<i>Thrombin digestion</i>	42
2.5	CHROMATOGRAPHY COLUMN AND MASS SPECTROMETRY	43
2.6	SUCROSE GRADIENTS	44
2.6.1	<i>Discontinuous gradients</i>	44
2.6.2	<i>Linear sucrose gradient</i>	44
2.7	RNA-PROTEIN BINDING EXPERIMENTS.....	45
2.7.1	<i>Homopolymer binding assay</i>	45
2.7.2	<i>Ephrin mRNAs-MID1 binding experiments</i>	45
2.7.2.1	<i>Amplification of G-quartets and EFNB1 mRNA</i>	45
2.7.2.2	<i>In vitro transcription of biotinylated RNA</i>	47
2.7.2.3	<i>Biotinylation Efficiency Dot Blot</i>	47
2.7.2.4	<i>RNA-PROTEIN Binding Assay</i>	47
2.7.3	<i>Bioinformatics</i>	48
3	RESULTS.....	49
3.1	CHARACTERISATION OF THE BBOXES OF MID1	49
3.1.1	<i>Mutations in Bbox1 disrupt MID1-α4 interaction</i>	49
3.1.2	<i>Analysis of the structure of the Bbox2 domain</i>	52
3.1.3	<i>C195F, mutated MID1 form found in an OS patient, disrupts MID1-α4 interaction</i>	53
3.1.4	<i>Bbox2 mutants do not interact with α4 in vivo</i>	55
3.1.5	<i>Bbox2 mutants interact with α4 in vitro</i>	59
3.2	CHARACTERISATION OF THE MID1 MULTIPROTEIN COMPLEX.....	62
3.2.1	<i>44aa peptide of α4 production in the PET32a vector system</i>	62
3.2.2	<i>α4-peptide production in the PinPoint vector system</i>	65
3.2.3	<i>Affinity chromatography column</i>	67
3.2.4	<i>Confirmation of novel MID1 interaction partners</i>	71
3.2.5	<i>The MID1 protein complex is found in purified microtubules</i>	71
3.2.6	<i>The MID1 complex associates with both ribosomal subunits</i>	72
3.2.7	<i>MID1 associates with intact ribosomes</i>	73
3.2.8	<i>MID1 forms part of a ribonucleoprotein complex</i>	74
3.2.9	<i>Characterisation of the association of MID1-FLAG with ribosomes</i>	76
3.2.9.1	<i>Salt and detergent treatments</i>	76
3.2.9.2	<i>EDTA treatment</i>	77

3.2.9.3	Puromycin and cycloheximide treatments	78
3.2.10	<i>Endogenous MID1 and other components of the complex associate with ribosomes</i>	79
3.2.11	<i>MID1 associates with polyribosomes</i>	80
3.2.12	<i>MID1 associates with homoribopolymers</i>	81
3.2.13	<i>Characterisation of the Poly-rG-MID1 binding</i>	82
3.2.14	<i>MID1 complex binds ephrin mRNA via G-quartet structures</i>	84
3.2.15	<i>Binding of the G-quartets to the MID1 Complex</i>	86
3.2.16	<i>MID1 complex associates with EFNBL1 mRNA</i>	87
4	DISCUSSION	89
4.1	A NOVEL PATHOMECHANISM FOR OS CAUSED BY MUTATIONS IN THE BBOXES DOMAINS OF MID1	89
4.2	THE MID1 MULTIPROTEIN COMPLEX	93
4.2.1	<i>MID1 forms part of a ribonucleoprotein complex</i>	93
4.2.2	<i>The components of the MID1 complex associate with microtubules</i>	94
4.2.3	<i>The MID1 complex and its role in translation at the microtubules</i>	95
4.2.4	<i>The MID1 complex and translational repression</i>	96
4.2.5	<i>MID1 complex and development of the ventral midline development: implications in cell migration</i>	98
4.2.6	<i>The MID1 complex components and their involvement in cell migration, polarisation and adhesion</i>	99
4.2.7	<i>EphB and ephrin-B mRNAs can be integrated in the MID1 complex</i>	101
5	CONCLUSIONS AND OUTLOOK	103
6	SUMMARY	105
7	SUMARIO	107
8	ZUSAMMENFASSUNG	109
9	REFERENCES	111
10	ABBREVIATIONS	126
11	CURRICULUM VITAE	129
12	PUBLICATIONS	130
13	ACKNOWLEDGEMENTS	131